<DOC>
	<DOCNO>NCT01225471</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical efficacy novel peptide vaccination advance prostate cancer</brief_summary>
	<brief_title>Novel Peptide Vaccination Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>Cell division cycle associate gene 1 ( CDCA1 ) identify use genome-wide expression profile analysis use cDNA microarray previous study . We determine HLA-A*2402 restrict epitope peptide derive CDCA1 , CDCA1-A24-56 . This epitope show strong IFN-g production stimulate appropriate target express appropriate protein HLA-A*2402 . Furthermore , vaccinate peptide , specific CTL determine vaccination . Therefore focus safety efficacy novel vaccination advance prostate cancer patient already show resistance standard hormonal therapy chemotherapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS advance prostate cancer already show resistance standard treatment PATIENTS CHARACTERISTICS 1 . Patients show resistance hormonal therapy chemotherapy 2 . Histological diagnosis adenocarcinoma 3 . HLAA*2402 4 . ECOG performance status 0 2 5 . Age ≥ 20 year , ≤85 year 6 . WBC≥ 2,000/mm³ , ≤12000/mm³ hemoglobin≥ 8.0g/dl Platelet count ≥ 70000/mm³ AST , ALT ≤100 IU/l Total bilirubin ≤ 1.5 mg/dl Creatinine ≤ 1.0 mg/dl PaO2≥ 70mmHg 7. life expectancy ≥ 2months 8 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Patients willing childbearing ( Refusal inability use effective mean contraception ) 4 . Serious infection require antibiotic 5 . Concomitant treatment steroid immunosuppressing agent 6 . Other malignancy difficult control . 7 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>novel epitope peptide</keyword>
	<keyword>CTL</keyword>
	<keyword>advanced prostate cancer</keyword>
</DOC>